Article
mRNA-lipid nanoparticles: Quality control releasing testing and characterization
![](https://content.labcorp.com/sites/default/files/biopharma_knowledge_library/whitepapers/mRNA-LNP-QC-AppNote-WPCMC010.pdf.png)
The regulatory authorizations and approvals of the Pfizer and Moderna COVID-19 vaccines proved to be a trailblazer for the mRNA-LNP modality and opened the pathway for regulatory approvals of a whole raft of similar mRNA-based products.